JP2022542430A - Ｆｃｒｎ抗体およびその使用の方法 - Google Patents

Ｆｃｒｎ抗体およびその使用の方法 Download PDF

Info

Publication number
JP2022542430A
JP2022542430A JP2022506356A JP2022506356A JP2022542430A JP 2022542430 A JP2022542430 A JP 2022542430A JP 2022506356 A JP2022506356 A JP 2022506356A JP 2022506356 A JP2022506356 A JP 2022506356A JP 2022542430 A JP2022542430 A JP 2022542430A
Authority
JP
Japan
Prior art keywords
minutes
seq
less
sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542430A5 (https=
Inventor
アロヨ，サンティアゴ
デニー，ウィリアム
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2022542430A publication Critical patent/JP2022542430A/ja
Publication of JP2022542430A5 publication Critical patent/JP2022542430A5/ja
Priority to JP2025093280A priority Critical patent/JP2025138661A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2022506356A 2019-08-01 2020-08-03 Ｆｃｒｎ抗体およびその使用の方法 Pending JP2022542430A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025093280A JP2025138661A (ja) 2019-08-01 2025-06-04 Ｆｃｒｎ抗体およびその使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881897P 2019-08-01 2019-08-01
US62/881,897 2019-08-01
PCT/US2020/044731 WO2021022249A1 (en) 2019-08-01 2020-08-03 Fcrn antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025093280A Division JP2025138661A (ja) 2019-08-01 2025-06-04 Ｆｃｒｎ抗体およびその使用の方法

Publications (2)

Publication Number Publication Date
JP2022542430A true JP2022542430A (ja) 2022-10-03
JP2022542430A5 JP2022542430A5 (https=) 2023-08-14

Family

ID=74229292

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506356A Pending JP2022542430A (ja) 2019-08-01 2020-08-03 Ｆｃｒｎ抗体およびその使用の方法
JP2025093280A Pending JP2025138661A (ja) 2019-08-01 2025-06-04 Ｆｃｒｎ抗体およびその使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025093280A Pending JP2025138661A (ja) 2019-08-01 2025-06-04 Ｆｃｒｎ抗体およびその使用の方法

Country Status (8)

Country Link
US (1) US20220259308A1 (https=)
EP (1) EP4007605A4 (https=)
JP (2) JP2022542430A (https=)
CN (1) CN114630678A (https=)
AU (1) AU2020319897A1 (https=)
CA (1) CA3148826A1 (https=)
MX (1) MX2022001380A (https=)
WO (1) WO2021022249A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
IL302516A (en) * 2020-11-06 2023-07-01 Janssen Biotech Inc FCRN antibodies and methods of using them
JP7755725B2 (ja) * 2021-08-13 2025-10-16 ジャンスー バイオジェッテイ バイオテクノロジー カンパニー リミテッド Ｆｃｒｎを特異的に認識する抗体およびその使用
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
AR131560A1 (es) * 2023-01-06 2025-04-09 argenx BV Métodos para tratar pots mediante el uso de antagonistas de fcrn
TW202527982A (zh) * 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
CN119326887B (zh) * 2024-10-20 2025-09-05 华中农业大学 动物FcRn蛋白在控制猪繁殖与呼吸综合征病毒感染性中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06217791A (ja) * 1992-04-01 1994-08-09 Merck & Co Inc Ｈｉｖ感染の予防及び治療のための組換えヒトｈｉｖ中和モノクローナル抗体
JP2011088913A (ja) * 2003-02-10 2011-05-06 Elan Pharmaceuticals Inc 免疫グロブリン製剤およびその調製の方法
JP2011523351A (ja) * 2008-04-25 2011-08-11 ダイアックス、コープ ＦｃＲｎに対する抗体及びその使用
WO2017189556A1 (en) * 2016-04-25 2017-11-02 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
WO2018055574A1 (en) * 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
WO2019070714A1 (en) * 2017-10-04 2019-04-11 Alexion Pharmaceuticals, Inc. ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRIPT
WO2019118791A1 (en) * 2017-12-13 2019-06-20 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
AU2011328246B2 (en) * 2010-11-08 2016-06-30 Ablynx N.V. CXCR2 binding polypeptides
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
RS64768B1 (sr) * 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
SMT202400004T1 (it) * 2016-07-29 2024-03-13 Momenta Pharmaceuticals Inc Anticorpi fcrn e loro metodi di utilizzo
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
CN113518783A (zh) * 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
JP2023509195A (ja) * 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
AU2021292200A1 (en) * 2020-06-17 2023-02-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of gene therapy patients

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06217791A (ja) * 1992-04-01 1994-08-09 Merck & Co Inc Ｈｉｖ感染の予防及び治療のための組換えヒトｈｉｖ中和モノクローナル抗体
JP2011088913A (ja) * 2003-02-10 2011-05-06 Elan Pharmaceuticals Inc 免疫グロブリン製剤およびその調製の方法
JP2011523351A (ja) * 2008-04-25 2011-08-11 ダイアックス、コープ ＦｃＲｎに対する抗体及びその使用
WO2017189556A1 (en) * 2016-04-25 2017-11-02 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
WO2018055574A1 (en) * 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
WO2019070714A1 (en) * 2017-10-04 2019-04-11 Alexion Pharmaceuticals, Inc. ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRIPT
WO2019118791A1 (en) * 2017-12-13 2019-06-20 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS MEDICINE, vol. 15(1), JPN6025003417, 2018, ISSN: 0005692589 *

Also Published As

Publication number Publication date
CA3148826A1 (en) 2021-02-04
JP2025138661A (ja) 2025-09-25
MX2022001380A (es) 2022-03-25
EP4007605A4 (en) 2023-08-16
CN114630678A (zh) 2022-06-14
US20220259308A1 (en) 2022-08-18
EP4007605A1 (en) 2022-06-08
AU2020319897A1 (en) 2022-02-24
WO2021022249A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
JP2022542430A (ja) Ｆｃｒｎ抗体およびその使用の方法
AU2022201145B2 (en) FcRn antibodies and methods of use thereof
JP7420720B2 (ja) ＦｃＲｎ抗体およびその使用方法
JP2022126783A (ja) Ｆｃｒｎ抗体及びその使用方法
US20220144946A1 (en) Fcrn antibodies and methods of use thereof
US20240084028A1 (en) Tetravalent anti-psgl-1 antibodies and uses thereof
EA050428B1 (ru) АНТИТЕЛА ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK40072884A (en) Fcrn antibodies and methods of use thereof
CN116782939A (zh) FcRn抗体及其使用方法
EA051865B1 (ru) Антитела к fcrn и способы их применения
JP2025526376A (ja) 中枢神経系疾患を識別または処置するための方法および系
EP4722252A1 (en) Antibody binding tissue factor pathway inhibitor and use of antibody

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20221020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250604